(Q39677100)

13 September 2017

title

Population-based screening for prostate cancer by measuring free and total serum prostate-specific antigen in Sweden (English)

1 reference

13 September 2017

0 references

1 reference

Hugosson J

1

1 reference

13 September 2017

Aus G

2

1 reference

13 September 2017

Bergdahl S

3

1 reference

13 September 2017

Fernlund P

4

1 reference

13 September 2017

Frösing R

5

1 reference

13 September 2017

Lodding P

6

1 reference

13 September 2017

Pihl CG

7

1 reference

13 September 2017

Lilja H

8

1 reference

13 September 2017

publication date

1 December 2003

1 reference

13 September 2017

1 reference

13 September 2017

volume

92 Suppl 2

1 reference

13 September 2017

page(s)

39-43

1 reference

Management of cancer of the prostate

13 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1465-5101.2003.04396.X

Second Stanford Conference on International Standardization of Prostate-Specific Antigen Immunoassays: September 1 and 2, 1994.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1465-5101.2003.04396.X

Diagnosis of advanced or noncurable prostate cancer can be practically eliminated by prostate-specific antigen

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1465-5101.2003.04396.X

The value of screening tests in the detection of prostate cancer. Part I: Results of a retrospective evaluation of 1726 men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1465-5101.2003.04396.X

Characteristics of screening detected prostate cancer in men 50 to 66 years old with 3 to 4 ng./ml. Prostate specific antigen

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1465-5101.2003.04396.X

Prostate cancer detection in men with serum PSA concentrations of 2.6 to 4.0 ng/mL and benign prostate examination. Enhancement of specificity with free PSA measurements

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1465-5101.2003.04396.X

The value of screening tests in the detection of prostate cancer. Part II: Retrospective analysis of free/total prostate-specific analysis ratio, age-specific reference ranges, and PSA density

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1465-5101.2003.04396.X

Measurement of the proportion of free to total prostate-specific antigen improves diagnostic performance of prostate-specific antigen in the diagnostic gray zone of total prostate-specific antigen

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1465-5101.2003.04396.X

Correlation of clinical and pathologic factors with rising prostate-specific antigen profiles after radical prostatectomy alone for clinically localized prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1465-5101.2003.04396.X

10.1111/J.1465-5101.2003.04396.X

21 January 2018

Identifiers

DOI

1 reference

13 September 2017

1 reference